Truist lowered the firm’s price target on Regeneron (REGN) to $940 from $975 but keeps a Buy rating on the shares. The firm is reducing its expected Eylea sales given the company’s near-term outlook, though while near-term investor focus remains on the Eylea tail, Regeneron continues to deliver growth on top/bottom line in the near to longer-term with Dupi and Libtayo, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $943 from $1,051 at RBC Capital
- Regeneron price target lowered to $633 from $768 at UBS
- Regeneron price target lowered to $587 from $652 at Baird
- Regeneron price target lowered to $800 from $865 at BMO Capital
- Regeneron price target lowered to $700 from $750 at Wells Fargo